腺癌是胃癌中最常见的组织学类型之一。它在常见癌症中位居第五位，是全球第三位致死癌症。胃癌患者的高死亡率是由于其悄无声息的演变、遗传异质性、对化疗的高抗性以及高度有效治疗策略的缺失。目前已经开发出并正在实施多种治疗策略，如手术、化疗、放疗和免疫治疗，然而还需要进一步的发展来改善治疗反应并减少副作用。因此，应该通过针对不同的检查点和关键免疫因子发展基于免疫反应的新型个性化治疗策略。靶向巨噬细胞及相关分子元素可以有助于实现这些目标。在本综述中，我们讨论了胃腺癌相关的现有治疗选择、分子基础和免疫调控。我们进一步描述了可能用于开发新型治疗选择的检查点和免疫靶点。版权所有 © 2023 Xu、Lin、Zeng、Ma、Nabi、Abidin、Wang和Wang。

Adenocarcinomas are one of the most common histological types of gastric cancer. It has been ranked fifth among common cancers and is the third among death causing cancers worldwide. The high mortality rate among patients with gastric cancer is because of its silent evolution, genetic heterogeneity, high resistance to chemotherapy as well as unavailability of highly effective therapeutic strategy. Until now a number of several treatment strategies have been developed and are being practiced such as surgery, chemotherapy, radio therapy, and immunotherapy, however, further developments are required to improve the treatment responses and reduce the side effects. Therefore, novel personal therapeutic strategies based on immunological responses should be developed by targeting different check points and key immune players. Targeting macrophages and related molecular elements can be useful to achieve these goals. In this minireview, we discuss the available treatment options, molecular underpinnings and immunological regulations associated with gastric adenocarcinoma. We further describe the possible check points and immunological targets that can be used to develop novel therapeutic options.Copyright © 2023 Xu, Lin, Zeng, Ma, Nabi, Abidin, Wang and Wang.